Article

Farnesyltransferase inhibition overcomes the adaptive resistance to osimertinib in <i>EGFR</i> -mutant NSCLC

2022-04-03

Abstract excerpt

<h4>ABSTRACT</h4> Drug-tolerant “dormant” cells (DTC) have emerged as one of the major non-genetic mechanisms driving resistance to targeted therapy in lung cancer, although the sequence of events leading to entry and exit from dormancy remain poorly described. Here, we performed real-time monitoring of the cell cycle dynamics during the adaptive response to Epidermal Growth Factor Receptor tyrosine kinase inhibi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ef132244-b648-5c9a-8233-eb6add7b2bf9
DOI: 10.1101/2022.04.01.486707

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Farnesyltransferase inhibition overcomes the adaptive resistance to osimertinib in <i>EGFR</i> -mutant NSCLCDOI 10.1101/2022.04.01.486707Read

Farnesyltransferase inhibition overcomes oncogene-addicted non-small cell lung cancer adaptive resistance to targeted therapiesSemantic proximity Read

Recurrent Escape from Osimertinib-Induced Senescence Promotes Genomic Instability Associated with Therapeutic ResistanceSemantic proximity Read

GSTA1 Conferred Tolerance to Osimertinib and Provided Strategies to Overcome Drug-Tolerant Persister in EGFR-Mutant Lung Adenocarcinoma.Semantic proximity Read

The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cellsSemantic proximity Read

The EGFR inhibitor osimertinib promotes a dynamic Drug Tolerant Persister state marked by replication defects and genome instabilitySemantic proximity Read

Reversible therapeutic resistance in <i>EGFR</i> mutant lung cancer caused by <i>RB1</i> loss induced lineage plasticitySemantic proximity Read

Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung CancerSemantic proximity Read

Neuroendocrine-like/EMT dedifferentiation mediates resistance to EGFR inhibitors via the NRG1/HER3 axisSemantic proximity Read

CRISPR Screens Reveal YAP/TEAD Axis as a Mediator of Drug-Tolerant Cells in EGFR- Mutant NSCLCSemantic proximity Read

Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer.Semantic proximity Read

Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway.Semantic proximity Read

Oncogene inactivation-induced senescence facilitates tumor relapseSemantic proximity Read